Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
Brian P. McDonough, MD, FAAFP
Matthew Galsky, MD
DESTINY-Breast11: Clinically Relevant Adverse Events
Charles E. Geyer Jr., MD, FACP
DESTINY-Breast05: Additional Data From the Interim Analysis
Dato-DXd in Non-Small Cell Lung Cancer: Implications of TROPION-Lung01 Data
Jacob Sands, MD
Julia Rotow, MD
Xiuning Le, MD, PhD
Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
Victoria Coleman-Cowger, PhD
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Brian Slomovitz, MD
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Ryan Quigley
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
Casey Cosgrove, MD
From Data to Debate: Global Perspectives on HR+/HER2- mBC Care
Giuseppe Curigliano, MD, PhD
Cynthia Villarreal-Garza, MD, DSc
Komal Jhaveri, MD, FACP
Hiraji Iwata, MD, PhD
Breaking New Ground in mCRC: Exploring Novel Targets in mCRC
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
Spotlight on Asia-Pacific: Practice Beyond Borders
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
Spotlight on Latin America: Closing the Gap
The Future of Oral SERDs: Combination Strategies
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.